Status:
COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Cancer, Advanced
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.
Eligibility Criteria
Inclusion
- Patients 18 years or older
- Must agree to consume high fat meal and agree to fasting conditions
- Limit alcohol consumption
Exclusion
- Patient has a history of drug or alcohol abuse within 5 years of start of study
- Patient is known to have HIV
- Patient has participated in another investigational study within 4 weeks of start of study
- Patient cannot stop taking certain medications or herbal remedies
- Patient will require immunologic, radiation, surgery, or chemotherapy during the study
- Patient requires frequent blood transfusions
- Female patient is pregnant or nursing
- Patient has an active Hepatitis B or C infection
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00750178
Start Date
November 1 2004
End Date
November 1 2005
Last Update
April 7 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.